{
  "id": "124",
  "title": "Molecular Subtypes of Endometrial Cancer: Classification, Prognosis, and Clinical Impact",
  "type": "Health",
  "img": "public/images/124.png",
  "section": "Endometrial cancer, arising from the lining of the uterus (endometrium), is a heterogeneous disease with varied outcomes and responses to treatment. Traditionally, it was classified based on histology (e.g., endometrioid, serous), but advances in genomic research have led to molecular subtyping—an approach that categorizes tumors by their genetic and molecular features. This breakthrough has transformed how clinicians predict prognosis, select therapies, and personalize care. This article explains the key molecular subtypes, their characteristics, and their impact on patient management.",
  "content": [
    "<p style=\"line-height: 2;\"><img src=\"public/images/124_content_0.png\" alt=\"\" width=\"1536\" height=\"864\"></p>\n<h4 style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><strong>What Is Molecular Subtyping of Endometrial Cancer?</strong></span></h4>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\">Molecular subtyping analyzes the genetic mutations, DNA methylation patterns, and protein expression of endometrial tumors to identify distinct subtypes. Unlike histology, which relies on tissue appearance under a microscope, molecular typing reveals the underlying biological drivers of the cancer. This allows for more precise predictions of how the tumor will behave (prognosis) and which treatments are most likely to work.</span></p>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\">The most widely adopted system, based on research from The Cancer Genome Atlas (TCGA), identifies four main molecular subtypes. These subtypes are consistent across different histologic types, making them a powerful tool for personalized care.</span></p>\n<h4 style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><strong>The Four Main Molecular Subtypes</strong></span></h4>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\">Each subtype has unique genetic features, clinical behaviors, and treatment implications:</span></p>\n<h5 style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><strong>1. POLE-ultramutated</strong></span></h5>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>Molecular <span style=\"font-family: 等线;\">特征 </span><span style=\"font-family: Arial;\">(Characteristics)</span></strong>: Tumors with mutations in the POLE gene, which is responsible for DNA repair. These mutations lead to an extremely high number of genetic errors (ultramutation), with thousands of mutations in the tumor genome.</span></p>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>Frequency</strong>: ~10% of endometrial cancers.</span></p>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>Clinical behavior</strong>: Excellent prognosis. These tumors rarely recur, even when diagnosed at advanced stages. The high mutation load creates “neoantigens” (abnormal proteins) that the immune system recognizes, aiding in tumor destruction.</span></p>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>Treatment implications</strong>: Typically treated with surgery alone; chemotherapy or radiation is often unnecessary due to the low recurrence risk.</span></p>\n<h5 style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><strong>2. Microsatellite Instable (MSI-H)</strong></span></h5>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>Molecular <span style=\"font-family: 等线;\">特征 </span><span style=\"font-family: Arial;\">(Characteristics)</span></strong>: Defects in DNA mismatch repair (MMR) genes (e.g., MLH1, MSH2, MSH6) cause errors in short repeated DNA sequences (microsatellites). This leads to a high mutation load, though lower than POLE-ultramutated tumors.</span></p>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>Frequency</strong>: ~25–30% of cases. Often linked to Lynch syndrome (an inherited genetic disorder that increases cancer risk) in ~30% of MSI-H cases.</span></p>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>Clinical behavior</strong>: Intermediate prognosis. Recurrence rates are higher than POLE-ultramutated but lower than other subtypes in early stages.</span></p>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>Treatment implications</strong>: Surgery is the foundation. For advanced or recurrent disease, immune checkpoint inhibitors (e.g., pembrolizumab) are highly effective, as MSI-H tumors are “visible” to the immune system.</span></p>\n<h5 style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><strong>3. Copy Number Low (CN-L; Previously “No Specific Molecular Profile”)</strong></span></h5>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>Molecular <span style=\"font-family: 等线;\">特征 </span><span style=\"font-family: Arial;\">(Characteristics)</span></strong>: Stable genomes with few changes in DNA copy numbers (no large-scale gains or losses of genetic material). Most are endometrioid histology (low-grade) and often linked to estrogen exposure.</span></p>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>Frequency</strong>: ~30–40% of endometrial cancers.</span></p>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>Clinical behavior</strong>: Good to intermediate prognosis, with recurrence rates lower than CN-H but higher than POLE or MSI-H in advanced stages.</span></p>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>Treatment implications</strong>: Surgery is primary. Adjuvant therapy (radiation or hormones) may be used for high-risk features (e.g., deep invasion into the uterus). Hormonal therapies (e.g., progestins) are often effective due to estrogen receptor expression.</span></p>\n<h5 style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><strong>4. Copy Number High (CN-H)</strong></span></h5>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>Molecular <span style=\"font-family: 等线;\">特征 </span><span style=\"font-family: Arial;\">(Characteristics)</span></strong>: Unstable genomes with widespread copy number changes (e.g., gains in oncogenes like HER2, losses in tumor suppressor genes). Often associated with TP53 mutations (a key tumor suppressor gene) and serous or high-grade endometrioid histology.</span></p>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>Frequency</strong>: ~20–25% of cases.</span></p>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>Clinical behavior</strong>: Poor prognosis. High recurrence rates, even in early stages, and aggressive growth patterns. These tumors are less responsive to standard therapies.</span></p>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>Treatment implications</strong>: Aggressive treatment is needed, including surgery, chemotherapy (e.g., carboplatin + paclitaxel), and sometimes radiation. For HER2-positive CN-H tumors, targeted therapies (e.g., trastuzumab) may improve outcomes.</span></p>\n<h4 style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><strong>How Molecular Subtyping Is Performed</strong></span></h4>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\">Testing is typically done on tumor tissue after surgery or biopsy, using a combination of methods:</span></p>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>Immunohistochemistry (IHC)</strong>: Detects MMR protein expression (to identify MSI-H). Absent MMR proteins indicate MSI-H.</span></p>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>POLE mutation analysis</strong>: Genetic sequencing to identify mutations in the POLE gene.</span></p>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>TP53 IHC or sequencing</strong>: Abnormal TP53 expression suggests CN-H subtype.</span></p>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>Genomic profiling</strong>: Next-generation sequencing (NGS) analyzes copy number changes and mutations to confirm subtypes, especially for CN-L and CN-H.</span></p>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\">Most labs use a stepwise approach: IHC for MMR and TP53, followed by POLE sequencing if needed, to classify tumors into one of the four subtypes.</span></p>\n<h4 style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><strong>Why Molecular Subtyping Matters for Patients</strong></span></h4>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>Prognosis prediction</strong>: It provides more accurate recurrence risk estimates than histology alone. For example, a low-grade endometrioid tumor classified as CN-H has a poorer prognosis than one classified as MSI-H.</span></p>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>Treatment personalization</strong>: Guides choices beyond standard care. For instance, MSI-H patients with recurrence can skip chemotherapy and go straight to immunotherapy.</span></p>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>Lynch syndrome screening</strong>: MSI-H tumors prompt genetic testing for Lynch syndrome, which affects 5–10% of endometrial cancer patients. Identifying Lynch syndrome allows for early screening of other cancers (e.g., colon, ovarian).</span></p>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>Clinical trial eligibility</strong>: Many trials target specific subtypes (e.g., CN-H with HER2 inhibitors), making subtyping essential for accessing novel therapies.</span></p>\n<h4 style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><strong>Common FAQs About Molecular Subtyping</strong></span></h4>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>When is molecular subtyping done?</strong> Typically after initial diagnosis, using tissue from the biopsy or surgical resection. Results take 1–2 weeks.</span></p>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>Is it covered by insurance?</strong> Yes, most insurance plans cover molecular testing for endometrial cancer, as it’s recommended by clinical guidelines.</span></p>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>Can subtypes change over time?</strong> Rarely, but recurrence or metastatic tumors may have additional mutations. Repeat testing on recurrent tissue may be done to guide further treatment.</span></p>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>How does it differ from traditional histology?</strong> Histology describes tumor appearance; molecular subtyping reveals genetic drivers. A single histologic type (e.g., endometrioid) can belong to different molecular subtypes with vastly different outcomes.</span></p>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\"><!-- [if !supportLists]--><span style=\"mso-list: Ignore;\">• </span><!--[endif]--><strong>Do all patients need molecular subtyping?</strong> Yes, guidelines recommend it for all endometrial cancer cases to optimize treatment and prognosis assessment.</span></p>\n<p class=\"15\" style=\"line-height: 2;\"><span style=\"font-size: 12pt;\">Molecular subtyping has revolutionized endometrial cancer care, moving beyond one-size-fits-all treatment to personalized strategies. By identifying POLE-ultramutated, MSI-H, CN-L, and CN-H subtypes, clinicians can tailor therapies, predict outcomes, and improve survival. For patients, understanding your subtype empowers informed discussions with your care team—whether about skipping unnecessary chemotherapy or accessing cutting-edge immunotherapies. As research advances, molecular subtyping will continue to refine how we prevent, diagnose, and treat this disease.</span></p>"
  ],
  "create_time": 1753687140
}